The Vaccine Adverse Event Reporting System (VAERS). 1994

R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333.

Immunizations against most vaccine-preventable diseases will be needed indefinitely unless the disease is eradicated. Public acceptance of immunizations may be threatened as vaccine coverage increases and disease decreases, however, due to the increase in both causally and coincidentally related vaccine adverse events. The post-marketing surveillance for such events in the USA in response to the mandatory reporting requirements of the National Childhood Injury Act of 1986. While VAERS has many methodological limitations intrinsic to such systems, it can play an important role in helping to monitor vaccine safety and maintain public confidence in immunizations.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D016907 Adverse Drug Reaction Reporting Systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. Adverse Drug Reaction Reporting System,Drug Reaction Reporting Systems, Adverse

Related Publications

R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
August 2015, Vaccine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
September 2021, Texas medicine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
August 2002, Vaccine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
January 2021, Vaccine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
September 2015, Pharmacoepidemiology and drug safety,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
July 1999, Vaccine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
September 2004, Pediatric annals,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
November 2012, Vaccine,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
October 2005, Pharmacoepidemiology and drug safety,
R T Chen, and S C Rastogi, and J R Mullen, and S W Hayes, and S L Cochi, and J A Donlon, and S G Wassilak
January 2023, Frontiers in public health,
Copied contents to your clipboard!